Heart, Lung and Circulation
Abstract| Volume 30, SUPPLEMENT 3, S100, 2021

In HFrEF Don’t Throw the Baby out with the Bathwater! SGLT2 inhibitors: Numbers Needed to Treat or Harm

      Sodium-glucose co-transport 2 (SGLT2) inhibitors are new therapeutic agents to cardiology. Initially intended as treatment for diabetes mellitus, clinical trials to demonstrate their cardiovascular safety have revealed significant cardiovascular benefits. The mechanisms for these benefits remain hypothetical but appear pleiotropic. Their adverse effect profile is diverse, with many being non-cardiovascular. This combination, along with therapeutic inertia, may lead to limited uptake due to risk-benefit concerns.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect